The neuroprotective role of creatine

Subcellular Biochemistry

Volumn 46, Issue , 2007, Pages 205-243

  Klein, Autumn M ^a,b   Ferrante, Robert J ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; NEUROPROTECTIVE AGENT;

ACUTE DISEASE; ANIMAL; CELL DEATH; CHRONIC DISEASE; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFECT; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; METABOLISM; NERVE CELL; REVIEW;

ACUTE DISEASE; ADENOSINE TRIPHOSPHATE; ANIMALS; CELL DEATH; CHRONIC DISEASE; CREATINE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 41549130338     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4020-6486-9_11     Document Type: Article

References (282)

1. Abe, K., Matsuo, Y., Kadekawa, J., Inoue, S., and Yanagihara, T., 1999, Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J. Neurol. Sci. 162: 65-68.
2. Adams, H., Adams, R., Del Zoppo, G., Goldstein, L.B., and Stroke Council of the American Heart Association, American Stroke Association, 2005, Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update: a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36: 916-923 (published corrections appear in Stroke 36: 1352 and Stroke 36: 1626).
3. Adcock, K.H., Nedelcu, J., Loenneker, T., Martin, E., Wallimann, T., and Wagner, B.P., 2002, Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Dev. Neurosci. 24: 382-388.
4. Aksenov, M., Aksenova, M., Butterfield, D.A., and Markesbery, W.R., 2000, Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74: 2520-2527.
5. Albin, R.L., and Greenamyer, J.T., 1992, Alternative excitotoxic hypotheses. Neurology 42: 733-738.
6. Alston, T.A., Mela, L., and Bright, H.J., 1977, 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl. Acad. Sci. USA 74: 3767-3771.
7. Andersen, P.M., Sims, K.B., Xin, W.W., Kiely, R., O'Neill, G., Ravits, J., Pioro, E., Harati, Y., Brower, R.D., Levine, J.S., Heinicke, H.U., Seltzer, W., Boss, M., and Brown, Jr. R.H., 2003, Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4: 62-73.
8. Andreassen, O.A., Dedeoglu, A., Ferrante, R.J., Jenkins, B.G., Ferrante, K.L., Thomas, M., Friedlich, A., Browne, S.E., Schilling, G., Borchelt, D.R., Hersch, S.M., Ross, C.A., and Beal, M.F., 2001a, Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8: 479-491.
9. Andreassen, O.A., Ferrante, R.J., Dedeoglu, A., and Beal, M.F., 2001b, Lipoic acid improves survival in transgenic mouse models of Huntington's disease. NeuroReport 12: 3371-3373.
10. Andreassen, O.A., Ferrante, R.J., Huang, H.M., Dedeoglu, A., Park, L., Ferrante, K.L., Kwon, J., Borchelt. D.R., Ross, C.A., Gibson, G.E., and Beal, M.F., 2001c, Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neurol. 50: 112-117.
11. + toxicity in an organotypic tissue culture system. Cell Transplant. 14: 537-550.
12. Anselm, I.M., Alkuraya, F.S., Salomons, G.S., Jakobs, C., Fulton, A.B., Mazumdar, M., Rivkin, M., Frye, R., Poussaint, T.Y., and Marsden, D., 2006, AX-linked creatine transporter defect: A report on two unrelated boys with a severe clinical phenotype. J. Inherit. Met. Dis. 29: 214-219.
13. Baker, S.K., and Tarnopolsky, M.A., 2003, Targeting cellular energy production in neurological disorders. Expert Opin. Investig. Drugs 12: 1655-1679.
14. Balestrino, M., Rebaudo, R., and Lunardi, G., 1999, Exogenous creatine delays anoxic depolarization and protects from hypoxic damage: dose-effect relationship. Brain Res. 816: 124-130.
15. Balsom, P.D., Soderlund, K., and Ekblom, B., 1994, Creatine in humans with special reference to creatine supplementation. Sports Med. 18: 268-280.
16. Baran, H., Heldt, R., and Hertting, G., 1987, Increased prostaglandin formation in rat brain following systemic application of kainic acid. Brain Res. 404: 107-112.
17. Barisic, N., Bernert, G., Ipsiroglu, O., Stromberger, C., Muller, T., Gruber, S., Prayer, D., Moser, E., Bittner, R.E., and Stöckler-Ipsiroglu, S., 2002, Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 33: 157-161.
18. Beal, M.F., 1992, Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31: 119-130.
19. Beal, M.F., 1995, Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38: 357-366.
20. Beal, M.F., 1996, Mitochondria, free radicals, and neurodegeneration. Curr. Opin. Neurobiol. 6: 661-666.
21. Beal, M.F., 2000, Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23: 298-304.
22. Beal, M.F., 2001, Mitochondria and oxidative damage in amyotrophic lateral sclerosis. Funct. Neurol. 16: 161-169.
23. Beal, M.F., 2003, Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 53 (Suppl. 3): S39-S47.
24. Beal, M.F., 2005, Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58: 495-505.
25. Beal, M.F., and Ferrante, R.J., 2004, Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5: 373-384.
26. Beal, M.F., Brouillet, E., Jenkins, B.G., Ferrante, R.J., Kowall, N.W., Miller, J.M., Storey, E., Srivastava, R., Rosen, B.R., and Hyman, B.T., 1993, Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13: 4181-4192.
27. Bence, N.F., Sampat, R.M., and Kopito, R.R., 2001, Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555.
28. Bender, A., Auer, D.P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., Bender, J., Weindl, A., Dose, M., Gasser, T., and Klopstock, T., 2005, Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol. 252: 36-41.
29. Bensimon, G., Lacomblez, L., Meininger, V., and The ALS/Riluzole Study Group, 1994, A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl. J. Med. 330: 585-591.
30. Berbel-Garcia, A., Barbera-Farre, J.R., Etessam, J.P., Salio, A.M., Cabello, A., Gutierrez-Rivas, E., and Campos, Y., 2004, Coenzyme Q10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin. Neuropharmacol. 27: 187-191.
31. Bernardi, P., Colonna, R., Costantini, P., Eriksson, O., Fontaine, E., Ichas, F., Massari, S., Nicolli, A., Petronilli, V., and Scorrano, L., 1998, The mitochondrial permeability transition. Biofactors 8: 273-281.
32. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F., 1973, Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20: 415-455.
33. Bessman, S.P., and Carpenter, C.L., 1985, The creatine-creatine phosphate energy shuttle. Annu. Rev. Biochem. 54: 831-862.
34. Bindoff, L.A., Birch-Machin, M.A., Farnsworthm L., Gardner-Medwin, D., Lindsay, J.G., and Turnbull, D.M., 1989, Familial intermittent ataxia due to a defect of the E1 component of pyruvate dehydrogenase complex. J. Neurol. Sci. 93: 311-318.
35. Blass, J.P., Sheu, R.F., and Gibson, G.E., 2000, Inherent abnormalities in energy metabolism in Alzheimer disease: Interaction with cerebrovascular compromise. Ann. N.Y. Acad. Sci. 903: 204-221.
36. Bloch, K., and Schoenheimer, R., 1941, The biological precursors of creatine. J. Biol. Chem. 138: 167-194.
37. Borthwick, G.M., Johnson, M.A., Ince, P.G., Shaw, P.J., and Turnbull, D.M., 1999, Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann. Neurol. 46: 787-790.
38. Bossy-Wetzel, E., Schwarzenbacher, R., and Lipton, S.A., 2004, Molecular pathways to neurodegeneration. Nat. Med. 10 (Suppl.): S2-S9.
39. Bove, J., Prou, D., Perier, C., and Przedborski, S., 2005, Toxin-induced models of Parkinson's disease. NeuroRx 2: 484-494.
40. Braissant, O., Henry, H., Loup, M., Eilers, B., and Bachmann, C., 2001, Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Brain Res. Mol. Brain Res. 86: 193-201.
41. Brennan, Jr. W.A., Bird, E.D., and Aprille, J.R., 1985, Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 44: 1948-1950.
42. Brewer, G.J., and Wallimann, T.W., 2000, Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J. Neurochem. 74: 1968-1978.
43. Brouillet, E., Jenkins, B.G., Hyman, B.T., Ferrante, R.J., Kowall, N.W., Srivastava, R., Roy, D.S., Rosen, B.R., and Beal, M.F., 1993, Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60: 356-359.
44. Brown, R.H., Jr, and Robberecht, W., 2001, Amyotrophic lateral sclerosis: Pathogenesis. Semin. Neurol. 21: 131-140.
45. Browne, S.E., and Beal, M.F., 1994, Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases. Biochem. Soc. Trans. 22: 1002-1006.
46. Browne, S.E., and Beal, M.F., 2004, The energetics of Huntington's disease. Neurochem. Res. 29: 531-546.
47. Browne, S.E., Ferrante, R.J., Beal, M.F., 1999, Oxidative stress in Huntington's disease. Brain Pathol. 9: 147-163.
48. Browne, S.E., Yang, L., DiMauro, J.P., Fuller, S.W., Licata, S.C., and Beal, M.F., 2006, Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol. Dis. 22: 599-610.
49. Bruijn, L.I., Becher, M.W,. Lee, M.K., Anderson, K.L., Jenkins, N.A., Copeland, N.G., Sisodia, S.S., Rothstein, J.D., Borchelt, D.R., Price, D.L., and Cleveland, D.W., 1997, ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: 327-338.
50. Bruijn, L.I., Miller, T.M., and Cleveland, D.W., 2004, Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosc. 27: 723-749.
51. Brustovetsky, N., Brustovetsky, T., and Dubinsky, J.M., 2001, On the mechanisms of neuroprotection by creatine and phosphocreatine. J. Neurochem. 76: 425-434.
52. Burneo, J.G., Knowlton, R.C., Faught, E., Martin, R., Sawrie, S., and Kunzniecky, R.I., 2004, Chronic temporal lobe epilepsy; spatial extent and degree of metabolic dysfunction studied with magnetic resonance spectroscopy (MRS). Epilepsy Res. 62: 119-124.
53. Candlish, E., La Croix, J., and Unrau, A.M., 1969, The biosynthesis of 3-nitropropionic acid in creeping indigo (Indigofera spicata). Biochemistry 8: 182-186.
54. Cardoso, S.M., Santana, I., Swerdlow, R.H., and Oliveira, C.R., 2004, Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem. 89: 1417-1426.
55. Carter, A.J., Muller, R.E., Pschorn, U., and Stransky, W., 1995, Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J. Neurochem. 64: 2691-2699.
56. Casademont, J., Rodriguez-Santiago, B., Miro, O., Beato, A., Lopez, S., Nunes, V., and Cardellach, F., 2005, Mitochondrial respiratory chain in brain homogenates: activities in different brain areas in patients with Alzheimer's disease. Aging Clin. Exp. Res. 17: 1-7.
57. Casey, A., and Greenhaff, P.L., 2000, Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am. J. Clin. Nutr. 72 (2 Suppl.): 607S-617S.
58. Cha, J.H., 2000, Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23: 387-392.
59. Chen, R.S., Huang, C.C., and Chu, N.S., 1997, Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur. Neurol. 37: 212-218.
60. Choudry, R.B., and Cudkowicz, M.E., 2005, Clinical trials in amyotrophic lateral sclerosis: The tenuous past and the promising future. J. Clin. Pharmacol. 45: 1334-1344.
61. Cleveland, D.W., and Rothstein, J.D., 2001, From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2: 806-819.
62. Cohen-Gadol, A.A., Pan, J.W., Kim, J.H., Spencer, D.D., and Hetherington, H.H., 2004, Mesial temporal lobe epilepsy; a proton magnetic resonance spectroscopy study and a histopathological analysis. J. Neurosurg. 1010: 613-620.
63. Dal Canto, M.C., and Gurney, M.E., 1994, Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676: 25-40.
64. Damier, P., Hirsch, E.C., Agid, Y., and Graybiel, A.M., 1999, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122: 1437-1448.
65. Dedeoglu, A., Kubilus, J.K., Yang, L., Ferrante, K.L., Hersch, S.M., Beal, M.F., and Ferrante, R.J., 2003, Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85: 1359-1367.
66. Dechent, P., Pouwels, P.J., Wilken, B., Hanefeld, F., and Frahm, J., 1999, Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am. J. Physiol. 277: R698-R704.
67. Desagher, S., and Martinou, J.C., 2000, Mitochondria as the central control point of apoptosis. Trends Cell Biol. 10: 369-377.
68. Desjardins, P., and Butterworth, R.F., 2005, Role of mitochondrial dysfunction and oxidative stress in the pathogenesis of selective neuronal loss in Wernicke's encephalopathy. Mol. Neurobiol. 31: 17-25.
69. Dhaliwal, G.K., and Grewal, R.P., 2000, Mitochondrial DNA deletion mutation levels are elevated in ALS brains. Neuroreport 11: 2507-2509.
70. Dichter, M., and Wilcox, K.S., 1997, Excitatory synaptic transmission. In: Engel, J., and Pedley, T.A. (eds.), Epilepsy: A Comprehensive Textbook. Lippincott Raven, Philadelphia, pp. 251-263.
71. Djousse, L., Knowlton, B., Cupples, L.A., Marder, K., Shoulson, I., and Myers, R.H., 2002, Weight loss in early stage of Huntington's disease. Neurology 59: 1325-1330.
72. Dudkin, K.N., Chueva, I.V., and Makarov, F.N., 2005, Interaction of sensory and cognitive processes during visual recognition: the role of the associative areas of the cerebral cortex. Neurosci. Behavioral Physiol. 35: 407-416.
73. Dupuis, L., Oudart, H,. René, F., Gonzalez de Aguilar, J-L., and Loeffler, J-P., 2004, Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. USA 101: 11159-11164.
74. Ferrante, K.L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M.F., Traynor, B., Newhall, K., Donofrio, P., Caress, J., Ashburn, C., Freiberg, B., O'Neill, C., Paladenech, C., Walker, T., Pestronk, A., Abrams, B., Florence, J., Renna, R., Schierbecker, J., Malkus, B., and Cudkowicz, M., 2005, Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65: 1834-1836.
75. Ferrante, R.J., Kowall, N.W., Beal, M.F., Richardson, Jr. E.P., Bird, E.D., and Martin, J.B., 1985, Selective sparing of a class of striatal neurons in Huntington's disease. Science 230: 561-563.
76. Ferrante, R.J., Kowall, N.W., and Richardson, Jr. E.P., 1991, Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11: 3877-3887.
77. Ferrante, R.J., Andreassen, O.A., Jenkins, B.G., Dedeoglu, A., Kuemmerle, S., Kubilus, J.K., Kaddurah-Daouk, R., Hersch, S.M., and Beal, M.F., 1999, Neuroprotective effects of creatine in a transgenic animal model of ALS. Nat. Med. 5: 347-350.
78. Ferrante, R.J., Andreassen, O.A., Dedeoglu, A., Kuemmerle, S., Kubilus, J.K., Kaddurah-Daouk, R., Hersch, S.M., and Beal, M.F., 2000, Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20: 4389-4397.
79. Ferrante, R.J., Andreassen, O.A., Dedeoglu, A., Ferrante, K.L., Jenkins, B.G., Hersch, S.M., and Beal, M.F., 2002, Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22: 1592-1599.
80. Festoff, B.W., Suo, Z., and Citron, B.A., 2003, Prospects for the pharmacotherapy of amyotrophic lateral sclerosis: old strategies and new paradigms for the third millennium. CNS Drugs 17: 699.
81. Foran, E., Del Signore, S.J., Markey, A., Matson, S., Smith, K.M., Cormier, K., Stack, E.C., Hersch, S.M., Ryu, H., and Ferrante, R.J., 2006, Dose ranging and efficacy study of high-dose creatine in Huntington's disease mouse models. Program No. 758.7/EE20, 2006 Neuroscience Meeting Planner, Atlanta, GA. Society for Neuroscience, Washington, DC, online (http://www.sfn.org).
82. Gabuzda, D., Busciglio, J., Chen, L.B., Matsudaira, P., and Yankner, B.A., 1994, Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 269: 13623-13628.
83. Gajewski, C.D., Lin, M.T., Cudkowicz, M.E., Beal, M.F., and Manfredi, G., 2003, Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells. Exp. Neurol. 179: 229-235.
84. Gasparini, L., Benussi, L., Bianchetti, A., Binetti, G., Curti, D., Govoni, S., Moraschi, S., Racchi, M., and Trabucchi, M., 1999, Energy metabolism inhibition impairs amyloid precursor protein secretion from Alzheimer's fibroblasts. Neurosci. Lett. 263: 197-200.
85. Gasparini, L., Racchi, M., Benussi, L., Curti, D., Binetti, G., Bianchetti, A., Trabucchi, M., and Govoni, S., 1997, Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci. Lett. 231: 113-117.
86. Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P., Rangone, H., Cordelieres, F.P., De Mey, J., MacDonald, M.E., Lessmann, V., Humbert, S., and Saudou, F., 2004, Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118: 127-138.
87. Graveland, G.A., Williams, R.S., and Difiglia, M.A., 1985, Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227: 770-773.
88. Green, D.R., and Reed, J.C., 1998, Mitochondria and apoptosis. Science 281: 1309-1312.
89. Greenhaff, P.L., Casey, A., Short, A.H., Harris, R., Soderlund, K., and Hultman, E., 1993, Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin. Sci. (London) 84: 565-571.
90. Groeneveld, G.J., Veldink, J.H., van der Tweel, I., Kalmijn, S., Beijer, C., de Visser, M., Wokke, J.H.J., Franssen, H., and van den Berg, L.H., 2003, A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 53: 437-445.
91. Grunewald, T., and Beal, M.F., 1999, Bioenergetics in Huntington's disease. Ann. N.Y. Acad. Sci. 893: 203-213.
92. Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M., and Schapira, A.H., 1996, Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39: 385-389.
93. Guerrero-Ontiveros, M.L., and Wallimann, T., 1998, Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol. Cell. Biochem. 184: 427-437.
94. Gurney, M.F., Pu, H., Chiu, A.Y., Dal Canto, M.C., Poichow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H-X., Chen, W., Zhai, P., Sufit, R.L., and Siddique, T., 1994, Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775.
95. Hagenfeldt, L., von Dobeln, U., Solders, G., and Kaijser, L., 1994, Creatine treatment in MELAS. Muscle Nerve 17: 1236-1237.
96. Haley, R.W., 2003, Excess incidence of ALS in young Gulf War veterans. Neurology 61: 750.
97. Hamilton, B.F., and Gould, D.H., 1987, Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta Neuropathol. (Berlin) 72: 286-297.
98. Harris, R.C., Soderlund, K., and Hultman, E., 1992, Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin. Sci. (London) 83: 367-374.
99. Hass, R.H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., and Shults, C.W., 1995, Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37: 714-722.
100. Hauser, W.A., and Kurland, L.T., 1975, The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 16: 1-66.
101. Hausmann, O.N., Fouad, K., Wallimann, T., and Schwab, M.E., 2002, Protective effects of oral creatine supplementation on spinal cord injury in rats. Spinal Cord 40: 449-456.
102. Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., and Evans, D.A., 2003, Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60: 1119-1122.
103. Heinanen, K., Nanto-Salonen, K., Komu, M., Erkintalo, M., Alanen, A., Heinonen, O.J., Pulkki, K., Nikoskelainen, E., Sipila, I., and Simell, O., 1999a, Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia. Eur. J. Clin. Invest. 29: 1060-1065.
104. Heinanen, K., Nanto-Salonen, K., Komu, M., Erkintalo, M., Heinonen, O.J., Pulkki, K., Valtonen, M., Nikoskelainen, E., Alanen, A., and Simell, O., 1999b, Muscle creatine phosphate in gyrate atrophy of the choroid and retina with hyperornithinaemia-clues to pathogenesis. Eur. J. Clin. Invest. 29: 426-431.
105. Helder, D.I., Kaptein, A.A., Van Kempen, G.M., Van Houwelingen, J.C., and Roos, R.A., 2001, Impact of Huntington's disease on quality of life. Mov. Disord. 16: 325-330.
106. Henshaw, R., Jenkins, B.G., Schulz, J.B., Ferrante, R.J., Kowall, N.W., Rosen, B.R., and Beal, M.F., 1994, Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res. 647: 161-166.
107. Hersch, S.M., and Ferrante, R.J., 2004, Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 1: 298-306.
108. Hersch, S.M., Rosas, H.D., and Ferrante, R.J., 2004, Neuropathology and pathophysiology of Huntington's disease, in movement disorders. In: Koller, W. (ed.), Neurologic Principles and Practice. McGraw-Hill, New York, pp. 503-526.
109. Hersch, S.M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., Ulug, A.M., Beal, M.F., Matson, W., Bogdanov, M., Ebbel, E., Zaleta, A., Kaneko, Y., Jenkins, B., Hevelone, N., Zhang, H., Yu, H., Schoenfeld, D., Ferrante, R.J., and Rosas, H.D., 2006, Creatine in Huntington's disease is safe, tolerable, and bioavailable in brain and reduces serum 8-OHDG. Neurology 66: 250-252.
110. Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A.H., Rudolf, J., Herholz, K., and Heiss, W.D., 2005, Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62: 378-382.
111. Hirano, A., Nakano, I., Kurland, L.T., Mulder, D.W., Holley, P.W., and Saccomanno, G., 1984, Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 43: 471-480.
112. Hirano, M., Kaufmann, P., DeVivo, D., and Kurenarai, T., 2006, Mitochondrial Neurology I: Encephalopathies. In: DiMauro, S., Hirano, S., and Schon, E. (eds.), Mitochondrial Medicine. Informa Healthcare, Oxon, pp. 27-44.
113. Holtzman, D., Khait, I., Mulkern, R., Allred, E., Rand, T., Jensen, F., and Kraft, R., 1999, In vivo development of brain phosphocreatine in normal and creatine-treated rabbit pups. J. Neurochem. 73: 2477-2484.
114. Holtzman, D., Togliatti, A., Khait, I., and Jensen, F., 1998, Creatine increases survival and suppresses seizures in the hypoxic immature rat. Pediatr. Res. 44: 410-414.
115. Horner, R.D., Kamins, K.G., Feussner, J.R., Grambow, S.C., Hoff-Lindquist, J., Harati, Y., Mitsumoto, H., Pascuzzi, R., Spencer, P.S., Tim. R., Howard, D., Smith, T.C., Ryan, M.A.K., Coffman, C.J., and Kasarskis, E.J., 2003, Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 61: 742.
116. Howell, N., Bindoff, L.A., McCullough, D.A., Kubacka, I., Poulton, J., Mackey, D., Taylor, L., and Turnbull, D.M., 1991, Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. Am. J. Hum. Genet. 49: 939-950.
117. Howland, D., Liu, J., She, Y., Goad, B., Maragakis, N., Kim, B., Erickson, J., Kulik, J., DeVito, L., Psaltis, G., DeGennaro, L., Cleveland, D., and Rothstein, J., 2002, Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. USA 99: 1604-1609.
118. Hoyer, S., 1993, Brain oxidative energy and related metabolism, neuronal stress, and Alzheimer's disease: a speculative synthesis. J. Geriatr. Psychiatry Neurol. 6: 3-13.
119. Huntington's Disease Collaborative Research Group, 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
120. Hwang, D.Y., Ardayfio, P., Kang, U.J., Semina, E.V., and Kim, K.S., 2003, Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114: 123-131.
121. Ihara, Y., Namba, R., Kuroda, S., Sato, T., and Shirabe, T., 1989, Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J. Neurol. Sci. 90: 263-271.
122. Ikeda, K., Iwasaki, Y., and Kinoshita, M., 2000, Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1: 207-12.
123. Item, C.B., Stöckler-Ipsiroglu, S., and Stromberger, C., 2001, Arginine:glycine amidinotransferase deficiency; the third inborn error of creatine metabolism in humans. Am. J. Hum. Genet. 69: 1127-1133.
124. Jaarsma, D., 2006, Swelling and vacuolisation of mitochondria in transgenic SOD1-ALS mice: a consequence of supranormal SOD1 expression? Mitochondrion 5: 77-87.
125. Jenkins, B.G., Koroshetz, W., Beal, M.F., and Rosen, B., 1993, Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 43: 2689-2695.
126. Jenkins, B.G., Rosas, H.D., Chen, Y.C., Makabe, T., Myers, R., MacDonald, M., Rosen, B.R., Beal, M.F., and Koroshetz, W.J., 1998, 1H-NMR spectroscopy studies of Huntington's disease. Neurology 50: 1357-1365.
127. Jiang, C., Wan, X., He, Y., Pan, T., Jankovic, J., and Le, W., 2005, Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 191: 154-162.
128. Jun, A.S., Brown, M.D., and Wallace, D.C., 1994, A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc. Natl. Acad. Sci. USA 91: 6206-6210.
129. Kaal, E., Vlug, A., Versleijen, M., Kuilman, M., Joosten, E., and Dop Bar, P., 2000, Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. J. Neurochem. 74: 1158-1165.
130. Kernec, F., Le Tallec, N., Nadal, L., Begue, J.M., and Le Rumeur, E., 1996, Phosphocreatine synthesis by isolated rat skeletal muscle mitochondria is not dependent upon external ADP: a 31P NMR study. Biochem. Biophys. Res. Commun. 225: 819-825.
131. Kieburtz, K., 2001, Placebo-controlled trial of creatine in Huntington's disease. Neurology 56 (Suppl. 3): A334.
132. Kiechle, T., Dedeoglu, A., Kubilus, J., Kowall, N.W., Beal, M.F., Friedlander, R.M., Hersch, S.M., and Ferrante, R.J., 2002, Cytochrome C and caspase-9 expression in Huntington's disease. Neuromol. Med. 1: 183-195.
133. Klivenyi, P., Ferrante, R.J., Matthews, R.T., Bogdanov, M.B., Klein, A.M., Andreassen, O.A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., and Beal, M.F., 1999, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5: 347-350.
134. Klivenyi, P., Gardian, G., Calingasan, N.Y., Yang, L., and Beal, M.F., 2003, Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Mol. Neurosci. 21: 191-198.
135. Klivenyi, P., Calingasan, N.Y., Starkov, A., Stavrovskaya, I.G., Kristal, B.S., Yang, L., Wieringa, B., and Beal, M.F., 2004, Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol. Dis. 15: 610-617.
136. Klivenyi, P., Kiaei, M., Gardian, G., Calingasan, N.Y., and Beal, M.F., 2004, Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 88: 576-582.
137. Komura, K., Hobbiebrunken, E., Wilichowski, E.K., and Hanefeld, F.A., 2003, Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr. Neurol. 28: 53-58.
138. Komura, K., Nakano, K., Ishigaki, K., Tarashima, M., Nakayama, T., Sasaki, K., Saito, K., and Osawa, M., 2006, Creatine monohydrate therapy in a Leigh syndrome patient with A8344G mutation. Pediatr. Int. 48: 409-412.
139. Kong, J., and Xu, Z., 1998, Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18: 3241-3250.
140. Koroshetz, W.J., Jenkins, B.G., Rosen, B.R., and Beal, M.F., 1997, Energy metabolism defects in Huntington's disease and possible therapy with coenzyme Q10. Ann. Neurol. 41: 160-165.
141. Kremer, B., Squitieri, F., Telenius, H., Andrew, S.E., Theilmann, J., Spence, N., Goldberg, Y.P., and Hayden, M.R., 1993, Molecular analysis of late onset Huntington's disease. J. Med. Genet. 30: 991-995.
142. Kremer, B.P., Goldberg, S., Andrew, J., Theilmann, J., Telenius, H., and Zeisler, J., Squitieri, F., Lin, B., Bassett, A., Almqvist, E., Bird, T., and Hayden, M.R., 1994, A worldwide study of the Huntington's disease mutation-the sensitivity and specificity of measuring CAG repeats. New Engl. J. Med. 330: 1401-1406.
143. Kuhl, D.E., Markham, C.H., Metter, E.J., Riege, W.H., Phelps, M.E., and Mazziotta, J.C., 1985, Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 63: 199-209.
144. Kuhl, D.E., Phelps, M.E., Markham, C.H., Metter, E.J., Riege, W.H., and Winter, J., 1982, Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 12: 425-434.
145. Kuwert, T., Lange, H.W., Langer, K.J., Herzog, H., Aulich, A., and Feinendegen, L.E., 1990, Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113: 1405-1423.
146. Lawler, J.M., Barnes, W.S., Wu, G., Song, W., and Demaree, S., 2002, Direct antioxidant properties of creatine. Biochem. Biophys. Res. Comm. 290: 47-52.
147. Liang, L.P., Ho, Y.S., and Patel, M., 2000, Mitochondrial superoxide production in kainate-induced hippocampal damage. Neuroscience 101: 563-570.
148. + mice. Free Radic. Biol. Med. 36: 542-554.
149. Lofberg, M., Lindholm, H., Naveri, H., Majander, A., Suomalainen, A., Paetau, A., Sovijarvi, A., Harkonen, M., and Somer, H., 2001, ATP, phosphocreatine and lactate in exercising muscle in mitochondrial disease and McArdle's disease. Neuromusc. Disord. 11: 370-375.
150. Loike, J.D., Zalutsky, D.L., Kaback, E., Miranda, A.F., and Silverstein, S.C., 1988, Extracellular creatine regulates creatine transport in rat and human muscle cells. Proc. Natl. Acad. Sci. USA 85: 807-811.
151. Loiseau, J., Loiseau, P., Guyot, M., Duche, B., Dartigues, J.F., and Aublet, B., 1990, Survey of seizure disorders in the French southwest. I. Incidence of epileptic syndromes. Epilepsia 31: 391-396.
152. Ludolph, A.C., He, F., Spencer, P.S., Hammerstad, J., and Sabri, M., 1991, 3-Nitropropionic acid- exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18: 492-498.
153. Ludolph, A.C., Seelig, M., Ludolph, A.G., Sabri, M.I., and Spencer, P.S., 1992, ATP deficits and neuronal degeneration induced by 3-nitropropionic acid. Ann. N.Y. Acad. Sci. 648: 300-302.
154. Malcon, C., Kaddurah-Daouk, R., and Beal, M.F., 2000, Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res. 860: 195-198.
155. Mancini, G.M., Catsman-Berrevoets, C.E., and deCoco, I.F., 2004, Two novel mutations in SLC6A8 deficiency in X-linked mental retardation. Am.J.Hum.Genet. 75: 97-105.
156. Mann, V.M., Cooper, J.M., Javoy-Agid, F., Agid, F., Jenner, P., and Schapira, A.H.V., 1990, Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336: 749.
157. Mark, R.J., Pang, Z., Geddes, J.W., Uchida, K., and Mattson, M.P., 1997, Amyloid peptide impairs glucose transport in hippocampal and cortical neurons: Involvement of membrane lipid peroxidation. J. Neurosci. 17: 1046-1054.
158. Mastrogiacomo, F., LaMarche, J., Dozic, S., Lindsay, G., Bettendorff, L., Robitaille, Y., Schut, L., and Kish, S.J., 1996, Immunoreactive levels of alpha-ketoglutarate dehydrogenase subunits in Friedreich's ataxia and spinocerebellar ataxia type 1. Neurodegeneration 5: 27-33.
159. Masui, Y., Mozai, T., and Kakehi, K., 1985, Functional and morphometric study of the liver in motor neuron disease. J. Neurol. 232: 15-19.
160. Masumizu, T., Noda, Y., Mori, A., and Packer, L., 2005, Electron spin resonance assay of ascorbyl radical generation in mouse hippocampal slices during and after kainate-induced seizures. Brain Res. Brain Res. Protoc. 16: 65-69.
161. Matsuishi, T., Sakai, T., Naito, E., Nagamitsu, S., Kuroda, Y., Iwashita, H., and Kato, H., 1996, Elevated cerebrospinal fluid lactate/pyruvate ratio in Machado-Joseph disease. Acta Neurol. Scand. 93: 72-75.
162. Matthews, R.T., Yang, L., Jenkins, B.G., Ferrante, R.J., Rosen, B.R., Kaddurah-Daouk, R., and Beal, M.F., 1998, Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18: 156-163.
163. Matthews, R.T., Ferrante, R.J., Klivenyi, P., Yang, L., Klein, A.M., Mueller, G., Kaddurah-Daouk, R., and Beal, M.F., 1999, Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157: 142-149.
164. Mattiazzi, M., D'Aurelio, M., Gajewski, C.D., Martushova, K., Kiaei, M., Beal, M.F., and Manfredi, G., 2002, Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 277: 29626-29633.
165. Mazziotta, J.C., Phelps, M.E., Pahl, J.J., Huang, S.C., Baxter, L.R., and Riege, W.H., Hoffman, J.M., Juhl, D.E., Lanto, A.B., Wapenski, J.A., et al., 1987, Reduced cerebral glucose metabolism in asymptomatic patients at risk for Huntington's disease. New Engl. J. Med. 316: 357-362.
166. McGeer, E.G., and McGeer, P.L., 2005, Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 19: 31.
167. Mecocci, P., MacGarvey, U., and Beal, M.F., 1994, Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36: 747-751.
168. Mercimek-Mahmutoglu, S., Stoeckler-Ipsiroglu, S., Adami, A., Appleton, R., Araujo, H.C., Duran, M., Ensenauer, R., Fernandez-Alvarez, E., Garcia, P., Grolik, C., Item, C.B., Leuzzi, V., Marquardt, I., Muhl, A., Saelke-Kellermann, R.A., Salomons, G.S., Schulze, A., Surtees, R., van der Knaap, M.S., Vasconcelos, R., Verhoeven, N.M., Vilarinho, L., Wilichowski, E., and Jakobs, C., 2006, GAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 67: 480-484.
169. Mesulam, M., 2000, A plasticity-based theory of the pathogenesis of Alzheimer's disease. Ann. N.Y. Acad. Sci. 924: 42-52.
170. Mettler, F.A., 1972, Neuropathological effects of sodium azide administration in primates. Fed. Proc. 31: 1504-1507.
171. Meyer, R.A., Sweeney, H.L., and Kushmerick, M.J., 1984, A simple analysis of the "phosphocreatine shuttle". Am. J. Physiol. 246: C365-C377.
172. Mikati, M.A., Kurdit, R.M., Rahmeh, A.A., Farhat, F., Abu Rialy, S., Lteif, L., Francis, E., Geha, G., and Maraashli, W., 2004, Effects of creatine and cyclocreatine supplementation on kainate induced injury in pre-pubescent rats. Brain Inj. 18: 1229-1241.
173. Miller, R.G., Mitchell, J.D., Lyon, M., and Moore, D.H., 2003, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4: 191.
174. Mueller, S.G., Laxer, K.D., Barbakos, J.A., Cashdollar, N., Flenniken, D.L., Vermathen, P., Matson, G.B., and Weiner, M.W., 2005, Metabolic characteristics of cortical malformations causing epilepsy. J. Neurol. 252: 1082-1092.
175. Mutisya, E.M., Bowling, A.C., and Beal, M.F., 1994, Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63: 2179-2184.
176. Myers, R.H., MacDonald, M.E., Koroshetz, W.J., Duyao, M.P., Ambrose, C.M., Taylor, S.A., Barnes, G., Srinidhi, J., Lin, C.S., Whaley, W.L., Lazzarini, A.M., Schwarz, M., Wolff, G., Bird, E.D., Vonsattel, J.-P.G., and Gusella, J.F., 1993, De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet. 5: 168-173.
177. Nakano, K., Hirayama, K., and Terai, K., 1987, Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch. Neurol. 44: 103-106.
178. Newbery, H.J., and Abbott, C.M., 2002, Of mice, men and motor neurons. Trends Mol. Med. 8: 88.
179. Nicklas, W.J., Vyas, I., and Heikkila, R.E., 1985, Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine. Life Sci. 36: 2503-2508.
180. NINDS NET-PD Investigators, 2006, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664-671.
181. Novelli, A., Reilly, J.A., Lysko, P.G., and Henneberry, R.C., 1988, Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451: 205-212.
182. Nunes, I., Tovmasian, L.T., Silva, R.M., Burke, R.E., and Goff, S.P., 2003, Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. USA 100: 4245-4250.
183. O'Gorman, E., Beutner, G., Wallimann, T., and Brdiczka, D., 1996, Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim. Biophys. Acta 1276: 161-170.
184. O'Gorman, E., Beutner, G., Dolder, M., Koretsky, A.P., Brdiczka, D., and Wallimann, T., 1997, The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 414: 253-257.
185. Okamoto, K., Hirai, S., Shoji, M., Senoh, Y., and Yamazaki, T., 1990, Axonal swellings in the corticospinal tracts in amyotrophic lateral sclerosis. Acta Neuropathol. 80: 222-226.
186. Olney, J.W., and de Gubareff, T., 1978a, Glutamate neurotoxicity and Huntington's chorea. Nature 271: 557-559.
187. Olney, J.W., and de Gubareff, T., 1978b, The fate of synaptic receptors in the kainite-lesioned striatum. Brain Res. 140: 340-343.
188. Palfi, S., Ferrante, R.J., Brouillet, E., Beal, M.F., Dolan, R., Guyot, M.C., Peschanski, M., and Hantraye, P., 1996, Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. Neuroscience 16: 3019-3025.
189. Pan, J.W., Kim, J.H., Cohen-Gadol, A., Pan, C., Spencer, D.D., and Hetherington, H.P., 2005, Regional energetic dysfunction in hippocampal epilepsy. Acta Neurol. Scand. 111: 218-224.
190. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J., and Greenamyre, J.T., 2002, Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5: 731-736.
191. Pappolla, M.A., Chyan, Y.J., Omar, R.A., Hsiao, K., Perry, G., Smith, M.A., and Bozner, P., 1998, Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152: 871-877.
192. Parker, W.D. Jr., and Parks, J.K., 1995, Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 45: 482-486.
193. Parker, W.D. Jr., Boyson, S.J., and Parks, J.K., 1989, Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26: 719-723.
194. Parker, W.D. Jr., Boyson, S.J., Luder, A.S., and Parks, J.K., 1990, Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 40: 1231-1234.
195. Pasinelli, P., Belford, B., Lennon, N., Bacskai, B., Hyman, B., Trotti, D., and Brown, R., 2004, Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43: 19-30.
196. Patel, M., 2004, Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures. Free Radic. Biol. Med. 37: 1951-1962.
197. Paulsen, J.S., Zhao, H., Stout, J.C., Brinkman, R.R., Guttman, M., Ross, C.A., Como, P., Manning, C., Hayden, M.R., Shoulson, I., and Huntington Study Group, 2001, Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57: 658-662.
198. Persky, A.M., and Brazeau, G.A., 2001, Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol. Rev. 53: 161-176.
199. Pettegrew, J.W., Panchalingam, K., Klunk, W.E., McClure, R.J., and Muenz, L.R., 1994, Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol. Aging 15: 117-132.
200. Prass, K., Royl, G., Lindauer, U., Freyer, D., Megow, D., Dirnagl, U., Stockler-Ipsiroglu, G., Wallimann, T., and Priller, J., 2007, Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow Metab. 27: 452-459.
201. Pratico, D., Uryu, K., Leight, S., Trojanoswki, J.Q., and Lee, V.M., 2001, Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21: 4183-4187.
202. Rabchevsky, A.G., Sullivan, P.G., Fugaccia, I., and Scheff, S.W., 2003, Creatine diet supplement for spinal cord injury: influences on functional recovery and tissue sparing in rats. J. Neurotrauma 20: 659-669.
203. Robitaille, Y., Lopes-Cendes, I., Becher, M., Rouleau, G., and Clark, A.W., 1997, The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol. 7: 901-926.
204. Rodrigo, J., Fernandez-Vizarra, P., Castro-Blanco, S., Bentura, M.L., Nieto, M., Gomez-Isla, T., Martinez-Murillo, R., MartInez, A., Serrano, J., and Fernandez, A.P., 2004, Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience 128: 73-89.
205. Rosen, D.R., Sapp, P., O'Regan, J., McKenna-Yasek, D., Schlumpf, K.S., Haines, J.L., Gusella, J.F., Horvitz, H.R., and Brown, R.H. Jr., 1993, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59.
206. Ross, C.A., 1997, Intranuclear neuronal inclusions: a common pathogenic mechanism for glutaminerepeat neurodegenerative diseases? Neuron 19: 1147-1150.
207. Ross, C.A., 2004, Huntington's disease: new paths to pathogenesis. Cell 118: 4-7.
208. Rothstein, J.D., 2003, Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann. Neurol. 53: 423-426.
209. Rothstein, J.D., Martin, L.J., and Kuncl, R.W., 1992, Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New Engl. J. Med. 326: 1464-1468.
210. Rothstein, J., Van Kammen, M., Levey, A., Martin, L., and Kuncl, R., 1995, Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38: 73-84.
211. Rowland, L., and Shneider, N., 2001, Amyotrophic lateral sclerosis. New Engl. J. Med. 344: 1688.
212. Roy, S., and Nicholson, D.W., 2000, Cross-talk in cell death signaling. J. Exp. Med. 192: 21-26.
213. Royes, L.F., Fighera, M.R., Furian, A.F., Oliveira, M.S., da Silva, L.G., Malfatti, C.R., Schneider, P.H., Braga, A.L., Wajner, M., and Mello, C.F., 2003, Creatine protects against the convulsive behavior and lactate production elicited by the intrastriatal injection of methylmalonate. Neuroscience 118: 1079-1090.
214. Royes, L.F., Fighera, M.R., Furian, A.F., Oliveira, M.S., Myskiw, J de C, Fiorenza, N.G., Petry, J.C., Coelho, R.C., and Mello, C.F., 2006, Effectiveness of creatine monohydrate on seizures and oxidative damage induced by methylmalonate. Pharmacol. Biochem. Behav. 83: 136-144.
215. Ryu, H., and Ferrante, R.J., 2005, Emerging chemotherapeutic strategies for Huntington's disease. Expert Opin. Emerg. Drugs 10: 345-363.
216. Ryu, H., Rosas, H.D., Hersch, S.M., and Ferrante, R.J., 2005, The therapeutic role of creatine in Huntington's disease. Pharmacol. Ther. 108: 193-207.
217. Sacco, R.L., Benjamin, E.J., Broderick, J.P., Dyken, M., Easton, J.D., Feinberg, W.M., Goldstein, L.B., Gorelick, P.B., Howard, G., Kittner, S.J., Manolio, T.A., Whisnant, J.P., and Wolf, P.A., 1997, American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke risk factors. Stroke 28: 1507-1517.
218. Sasaki, S., and Iwata, M., 1996, Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 47: 535-540.
219. Scaglia, F., and Northrop, J.L., 2006, The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 20: 443-464.
220. Scheff, S.W., and Dhillon, H.S., 2004, Creatine-enhanced diet alters levels of lactate and free fatty acids after experimental brain injury. Neurochem. Res. 29: 469-479.
221. Schloss, P., Mayser, W., and Betz, H., 1994, The putative rat choline transporter CHOT1 transports creatine and is highly expressed in neural and muscle-rich tissues. Biochem. Biophys. Res. Commun. 198: 637-645.
222. Schulz, J.B., Matthews, R.T., Jenkins, B.G., Ferrante, R.J., Siwek, D., Henshaw, D.R., Cipolloni, P.B., Mecocci, P., Kowall, N.W., and Rosen, B.R., 1995, Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 15: 8419-8429.
223. Shear, D.A., Haik, K.L., and Dunbar, G.L., 2000, Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. NeuroReport 11: 1833-1837.
224. Shefner, J.M., Cudkowicz, M.E., Schoenfeld, D., Conrad, T., Taft, J., Chilton, M., Urbinelli, L., Qureshi, M., Zhang, H., Pestronk, A., Caress, J., Donofrio, P., Sorenson, E., Bradley, W., Lomen-Hoerth, C., Pioro, E., Rezania, K., Ross, M., Pascuzzi, R., Heiman-Patterson, T., Tandan, R., Mitsumoto, H., Rothstein, J., Smith-Palmer, T., MacDonald, D., Burke, D.; NEALS Consortium, 2004, A clinical trial of creatine in ALS. Neurology 63: 1656-1661.
225. Shin, E.J., Suh, S.K., Lim, Y.K., Jhoo, W.K., Hjelle, O.P., Ottersen, O.P., Shin, C.Y., Ko, K.H., Kim, W.K., Kim, D.S., Chun, W., Ali, S., and Kim, H.C., 2005, Ascorbate attenuates trimethyltininduced oxidative burden and neuronal degeneration in the rat hippocampi by maintaining glutathione homeostasis. Neuroscience 133: 715-727.
226. Shinkai, T., Nakashima, M., Ohmori, O., Terao, T., Nakamura, J., Hiramatsu, N., Hashiguchi, H., and Tsuji, S., 2000, Coenzyme Q10 improves psychiatric symptoms in adult-onset mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: a case report. Aust. NZ J. Psychiatry 34: 1034-1035.
227. Shoffner, J.M., Lott, M.T., Lezza, A.M.S., Seibel, P., Ballinger, S.W., and Wallace, D.C., 1990, Myoclonic epilepsy and red-ragged fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 61: 931-937.
228. Shoffner, J., 1997, Oxidative phosphorylation defects and Alzheimer's disease. Neurogenetics 1: 13-19.
229. Simon, H.H., Saueressig, H., Wurst, W., Goulding, M.D., and O'Leary, D.D., 2001, Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci. 21: 3126-3134.
230. Smith, G.E., Bohac, D.L., Waring, S.C., Kokmen, E., Tangalos, E.G., Ivnik, R.J., and Petersen, R.C., 1998, Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 50: 355-362.
231. Smith, M.A., Hirai, K., Hsiao, K., Pappolla, M.A., Harris, P.L., Siedlak, S.L., Tabaton, M., and Perry, G., 1998, Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem.70: 2212-2215.
232. Smith, K.M., Matson, S., Matson, W.R., Cormier, K., Del Signore, S.J., Hagerty, S.W., Stack, E.C., Ryu, H., and Ferrante, R.J., 2006, Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762: 616-626.
233. Snow, R.J., and Murphy, R.M., 2001, Creatine and the creatine transporter: a review. Mol. Cell. Biochem. 224: 169-181.
234. Stöckler, S., Hanefeld, F., and Frahm, J., 1996a, Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 348: 789-790.
235. Stöckler, S., Isbrandt, D., Hanefeld, F., Schmidt, B., and von Figura, K., 1996b, Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man. Am. J. Hum. Genet. 58: 914-922.
236. Stockler, S., Schutz, P.W., and Salomons, G.S., 2007, Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Subcell. Biochem. 46: 149-166.
237. Stromberger, C., Bodamer, O.A., and Stöckler-Ipsiroglu, S., 2003, Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J. Inher. Metab. Dis. 26: 299-308.
238. Sullivan, P.G., Keller, J.N., Mattson, M.P., and Scheff, S.W., 1998, Traumatic brain injury alters synaptic homeostasis: implications for impaired mitochondrial and transport function. J. Neurotrauma 15: 789-798.
239. Sullivan, P.G., Bruce-Keller, A.J., Rabchevsky, A.G., Christakos, S., Clair, D.K., Mattson, M.P., and Scheff, S.W., 1999, Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J. Neurosci. 19: 6248-6256.
240. Sullivan, P.G., Geiger, J.D., Mattson, M.P., and Scheff, S.W., 2000, Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 48: 723-729.
241. Sullivan, P.G., Rippy, N.A., Dorenbus, K., Concepcion, R.C., Agarwal, A.K., and Rho, J.M., 2004, The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann. Neurol. 55: 576-580.
242. Sugars, K.L., and Rubinsztein, D.C., 2003, Transcriptional abnormalities in Huntington disease. Trends Genet. 19: 233-238.
243. Swerdlow, R.H., Parks, J.K., Cassarino, D.S., Maguire, D.J., Maguire, R.S., Bennett, J.P. Jr, Davis, R.E., and Parker, W.D. Jr., 1997, Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 49: 918-925.
244. Swerdlow, R.H., Parks, J.K., Cassarino, D.S., Trimmer, P.A., Miller, S.W., Maguire, D.J., Sheehan, J.P., Maguire, R.S., Pattee, G., Juel, V.C., Phillips, L.H., Tuttle, J.B., Bennett, J.P., Jr., Davis, R.E., and Parker, W.D. Jr., 1998, Mitochondria in sporadic amyotrophic lateral sclerosis. Exp. Neurol. 153: 135-142.
245. Sykut-Cegielska, J., Gradowska, W., Mercimek-Mahmutoglu, S., and Stöckler-Ipsiroglu, S., 2004, Biochemical and clinical characteristics of creatine deficiency syndromes. Acta Biochim. Pol. 51: 875-882.
246. Szebenyi, G., Morfini, G.A., Babcock, A., Gould, M., Selkoe, K., Stenoien, D.L., Young, M., Faber, P.W., MacDonald, M.E., McPhaul, M.J., and Brady, S.T., 2003, Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40: 41-52.
247. Tabrizi, S.J., Blamire, A.M., Manners, D.N., Rajagopalan, B., Styles, P., Schapira, A.H., and Warner, T.T., 2003, Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 61: 141-142.
248. Tan, D., Manchester, L.C., Reiter, R.J., Qi, W., Kim, S.J., and El-Sokkary, G.H., 1998, Melatonin protects hippocampal neurons in vivo against kainic acid-induced damage in mice. J. Neurosci. Res. 54: 382-389.
249. Taoka, Y., and Okajima, K., 1998, Spinal cord injury in the rat. Prog. Neurobiol. 56: 341-358.
250. Tarnopolsky, M.A., and Beal, M.F., 2001, Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 49: 561-574.
251. Tarnopolsky, M., and Martin, J., 1999, Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52: 854-857.
252. Tarnopolsky, M.A., Atkinson, S.A., MacDougall, J.D., Chesley, A., Phillips, S., and Schwarcz, H.P., 1992, Evaluation of protein requirements for trained strength athletes. J. Appl. Physiol. 73: 1986-1995.
253. Tarnopolsky, M.A., Roy, B.D., and MacDonald, J.R., 1997, A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20: 1502-1509.
254. Tarnopolsky, M.A., Maguire, J., Myint, T., Applegarth, D., and Robinson, B.H., 1998, Clinical, physiological, and histological features in a kindred with the T3271C melas mutation. Muscle Nerve 21: 25-33.
255. Tatsumi, T., Shiraishi, J., Keira, N., Akashi, K., Mano, A., Yamanaka, S., Matoba, S., Fushiki, S., Fliss, H., and Nakagawa, M., 2003, Intracellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes. Cardiovasc. Res. 59: 428-440.
256. Tellez-Nagel, I., Johnson, A.B., and Terry, R.D., 1974, Studies on brain biopsies of patients with Huntington's chorea. J. Neuropathol. Exp. Neurol.33: 308-332.
257. Theodore, W.H., 1999, Cerebral blood flow and glucose metabolism in human epilepsy. Adv. Neurol. 79: 873-881.
258. Tombes, R.M., and Shapiro, B.M., 1985, Metabolite channeling: a phosphorylcreatine shuttle to mediate high energy phosphate transport between sperm mitochondrion and tail. Cell 41: 325-334.
259. Trushina, E., Dyer, R.B., Badger, 2nd J.D., Ure, D., Eide, L., Tran, D.D., Vrieze, B.T., Legendre-Guillemin, V., McPherson, P.S., Mandavilli, B.S., Van Houten, B., Zeitlin, S., McNiven, M., Aebersold, R., Hayden, M., Parisi, J.E., Seeberg, E., Dragatsis, I., Doyle, K., Bender, A., Chacko, C., and McMurray, C.T., 2004, Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 24: 8195-8209.
260. Ueda, Y., Doi, T., Tokumaru, J., Makajima, A., and Nagatomo, K., 2005, In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainate acid-induced seizure status in rats. Neurochem. Res. 30: 1117-1121.
261. Van Brussel, E., Yang, J.J., and Seraydarian, M.W., 1983, Isozymes of creatine kinase in mammalian cell cultures. J. Cell. Physiol. 116: 221-226.
262. van den Munckhof, P., Luk, K.C., Ste-Marie, L., Montgomery, J., Blanchet, P.J., Sadikot, A.F., and Drouin, J., 2003, Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130: 2535-2542.
263. Verbessem, P., Lemiere, J., Eijnde, B.O., Swinnen, S., Vanhees, L., Van Leemputte, M., Hespel, P., and Dom, R., 2003, Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61: 925-930.
264. Verhoeven, N.M., Salomons, G.S., and Jakobs, C., 2005, Laboratory diagnosis of creatine synthesis and biotransport. Clin. Chim. Acta 361: 1-9.
265. Walker, J.B., 1979, Creatine: biosynthesis, regulation, and function. Adv. Enzymol. Relat. Areas Mol. Biol. 50: 177-242.
266. Walter, M.C., Reilich, P., Lochmuller, H., Kohnen, R., Schlotter, B., Hautmann, H., Dunkl, E., Pongratz, D., and Muller-Felber, W., 2002, Creatine monohydrate in myotonic dystrophy: a doubleblind, placebo-controlled clinical study. J. Neurol. 249: 1717-1722.
267. Webster, M.T., Pearce, B.R., Bowen, D.M., and Francis, P.T., 1998, The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J. Neural Transm. 105: 839-853.
268. Weisskopf, M.G., O'Reilly, E.J., McCullough, M.L., Calle, E.E., Thun, M.J., Cudkowicz, M., and Ascherio, A., 2005, Prospective study of military service and mortality from ALS. Neurology 64: 32.
269. Wiedemann, F.R., Manfredi, G., Mawrin, C., Beal, M.F., and Schon, E.A., 2002, Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J. Neurochem. 80: 616-625.
270. Wilken, B., Ramirez, J.M., Probst, I., Richter, D.W., and Hanefeld, F., 2000, Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation. Arch. Dis. Child Fetal Neonatal Ed. 82: F224-F227.
271. Williamson, A., Patrylo, P.R., Pan, J., Spencer, D.D., and Hetherington, H., 2005, Correlations between granule cell physiology and bioenergects in human temporal lobe. Brain 128: 1199-1208.
272. Willott, C.A., Young, M.E., Leighton, B., Kemp, G.J., Boehm, E.A., Radda, G.K., and Clarke, K., 1999, Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin. Acta Physiol. Scand. 166: 99-104.
273. Wong, P., Pardo, C., Borchelt, D., Lee, M., Copeland, N., Jenkins, N., Sisodia, S., Cleveland, S., and Price, D., 1995, An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105-1116.
274. Wyss, M., and Kaddurah-Daouk, R., 2000, Creatine and creatinine metabolism. Physiol. Rev. 80: 1107-1213.
275. Wyss, M., and Schulze, A., 2002, Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience 112: 243-260.
276. Xiong, Y., Peterson, P.L., Muizelaar, J.P., and Lee, C.P., 1997, Amelioration of mitochondrial function by a novel antioxidant U-101033E following traumatic brain injury in rats. J. Neurotrauma 14: 907-917.
277. Xiong, Y., Peterson, P.L., Verweij, B.H., Vinas, F.C., Muizelaar, J.P., and Lee, C.P., 1998, Mitochondrial dysfunction after experimental traumatic brain injury: combined efficacy of SNX-111 and U-101033E. J. Neurotrauma 15: 531-544.
278. Xu, C.J., Klunk, W.E., Kanfer, J.N., Xiong, Q., Miller, G., and Pettegrew, J., 1996, Phosphocreatinedependent glutamate uptake by synaptic vesicles. A compaison with ATP-dependent glutamate uptake. J. Biol. Chem. 271: 13435-13440.
279. Zeevalk, G.D., and Nicklas, W.J., 1991, Mechanisms underlying initioation of excitotoxicity associated with metabolic inhibition. J. Pharmacol. Exp. Ther. 257: 870-878.
280. Zhang, W., Narayanan, M., and Friedlander, R.M., 2003, Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53: 267-270.
281. Zhu, S., Stavrovskaya, I.G., Drozda, M., Kim, B.Y.S., Ona, V., Li, M., Sarang, S., Liu, A.S., Hartley, D.M., Wuk, D.C., Gullans, S., Ferrante, R.J., Przedborskikq, S., Kristal, B.S., and Friedlander, R.M., 2002, Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78.
282. Zhu, S., Li, M., Figueroa, B.E., Liu, A., Stavrovskaya, I.G., Pasinelli, P., Beal, M.F., Brown, R.H. Jr., Kristal, B.S., Ferrante, R.J., and Friedlander, R.M., 2004, Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 24: 5909-5912.